Market AdoptionThe Bimzelx launch continues to outperform, driven by strong patient adoption in multiple conditions and improved formulary positioning.
Regulatory ApprovalAnalysts are optimistic about Bimzelx's anticipated FDA approval for hidradenitis suppurativa.
Sales PerformanceBimzelx H2 sales reached €393MM, with US contribution significantly above consensus, indicating strong market performance.